Abstract
Aim:
Hyperoside is a flavonol glycoside mainly found in plants of the genera Hypericum and Crataegus, which has shown anti-oxidant, anti-cancer and anti-inflammatory activities. In this study, we investigated the effects of hyperoside on human rheumatoid fibroblast-like synoviocytes (FLSs) in vitro and on mouse collagen-induced arthritis (CIA) in vivo.
Methods:
FLSs were isolated from primary synovial tissues obtained from rheumatoid arthritis (RA) patients and exposed to LPS (1 μg/mL). Cell viability and proliferation were measured with MTT and BrdU assay. Cell migration was assessed using wound-healing assay and Transwell assay. DNA binding of NF-κB was measured using a TransAM-NFkappaB kit. The localization of p65 subunit was detected with immunocytochemistry. CIA was induced in mice by primary immunization with Bovine Type II collagen (CII) emulsified in CFA, followed by a booster injection 3 weeks later. The arthritic mice were treated with hyperoside (25, 50 mg·kg−1·d−1, ip) for 3 weeks, and the joint tissues were harvested for histological analysis.
Results:
Hyperoside (10, 50, 100 μmol/L) dose-dependently inhibited LPS-induced proliferation and migration of human RA FLSs in vitro. Furthermore, hyperoside decreased LPS-stimulated production of TNF-α, IL-6, IL-1 and MMP-9 in the cells. Moreover, hyperoside inhibited LPS-induced phosphorylation of p65 and IκBα, and suppressed LPS-induced nuclear translocation of p65 and DNA biding of NF-κB in the cells. Three-week administration of hyperoside significantly decreased the clinical scores, and alleviated synovial hyperplasia, inflammatory cell infiltration and cartilage damage in mice with CIA.
Conclusion:
Hyperoside inhibits LPS-induced proliferation, migration and inflammatory responses in human RA FLSs in vitro by suppressing activation of the NF-κB signaling pathway, which contributes to the therapeutic effects observed in mice with CIA.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T . Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 669–75.
Bottini N, Firestein GS . Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013; 9: 24–33.
Bartok B, Firestein GS . Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233–55.
Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR . Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997; 94: 10895–900.
Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S . Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1: 102–10.
McInnes IB, Schett G . Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429–42.
Koch AE . Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005; 52: 710–21.
Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000; 165: 1652–8.
Murphy G, Nagase H . Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290–308.
Vincenti MP, Coon CI, Brinckerhoff CE . Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 1998; 41: 1987–94.
Barchowsky A, Frleta D, Vincenti MP . Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000; 12: 1469–79.
Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998; 95: 15671–6.
di Meglio P, Ianaro A, Ghosh S . Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 2005; 52: 951–8.
Handel ML, McMorrow LB, Gravallese EM . Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38: 1762–70.
Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583–91.
Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum 2010; 62: 2313–21.
Okazaki Y, Sawada T, Nagatani K, Komagata Y, Inoue T, Muto S, et al. Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J Rheumatol 2005; 32: 1440–7.
Campbell IK, Gerondakis S, O'Donnell K, Wicks IP . Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000; 105: 1799–806.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M . Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286–90.
Yin MJ, Yamamoto Y, Gaynor RB . The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77–80.
Majumdar S, Aggarwal BB . Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001; 167: 2911–20.
Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532–42.
Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH . Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2009; 378: 90–4.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594–602.
Feldmann M . Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364–71.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761–9.
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011; 38: 1258–64.
Nishimoto N, Ito K, Takagi N . Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010; 20: 222–32.
Zou Y, Lu Y, Wei D . Antioxidant activity of a flavonoid-rich extract of Hypericum perforatum L in vitro. J Agric Food Chem 2004; 52: 5032–9.
Li HB, Yi X, Gao JM, Ying XX, Guan HQ, Li JC . The mechanism of hyperoside protection of ECV-304 cells against tert-butyl hydroperoxide-induced injury. Pharmacology 2008; 82: 105–13.
Li FR, Yu FX, Yao ST, Si YH, Zhang W, Gao LL . Hyperin extracted from Manchurian rhododendron leaf induces apoptosis in human endometrial cancer cells through a mitochondrial pathway. Asian Pac J Cancer Prev 2012; 13: 3653–6.
Kim SJ, Um JY, Lee JY . Anti-inflammatory activity of hyperoside through the suppression of nuclear factor-kappaB activation in mouse peritoneal macrophages. Am J Chin Med 2011; 39: 171–81.
Ku SK, Zhou W, Lee W, Han MS, Na M, Bae JS . Anti-inflammatory effects of hyperoside in human endothelial cells and in mice. Inflammation 2015; 38: 784–99.
Ku SK, Kwak S, Kwon OJ, Bae JS . Hyperoside inhibits high-glucose-induced vascular inflammation in vitro and in vivo. Inflammation 2014; 37: 1389–400.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
Lee YR, Lee JH, Noh EM, Kim EK, Song MY, Jung WS, et al. Guggulsterone blocks IL-1beta-mediated inflammatory responses by suppressing NF-kappaB activation in fibroblast-like synoviocytes. Life Sci 2008; 82: 1203–9.
Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 2001; 29: E21.
Lee YR, Hwang JK, Lee HS, Cheon YJ, Ryu JH, Lee SI, et al. SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis. Br J Pharmacol 2011; 164: 794–806.
Qu Z, Garcia CH, O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT . Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994; 37: 212–20.
Wang LY, Wang HY, Ouyang J, Yu L, Chen B, Qin JQ, et al. Low concentration of lipopolysaccharide acts on MC3T3-E1 osteoblasts and induces proliferation via the COX-2-independent NFkappaB pathway. Cell Biochem Funct 2009; 27: 238–42.
Murphy G, Nagase H . Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 2008; 4: 128–35.
Li G, Liu D, Zhang Y, Qian Y, Zhang H, Guo S, et al. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-kappaB-mediated matrix metalloproteinase-9 expression. PLoS One 2013; 8: e68905.
Pahl HL . Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853–66.
Boissier MC . Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 2011; 78: 230–4.
Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB . IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049–55.
Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S . Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62: 383–91.
Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002; 61: 975–80.
Ou Y, Li W, Li X, Lin Z, Li M . Sinomenine reduces invasion and migration ability in fibroblast-like synoviocytes cells co-cultured with activated human monocytic THP-1 cells by inhibiting the expression of MMP-2, MMP-9, CD147. Rheumatol Int 2011; 31: 1479–85.
Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52–67.
Bjorklund M, Koivunen E . Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37–69.
Richardson VJ . Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int J Immunopathol Pharmacol 2010; 23: 715–26.
Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50: 2942–53.
Okamoto T . NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006; 6: 359–72.
Kawai T, Akira S . TLR signaling. Cell Death Differ 2006; 13: 816–25.
Boyle WJ, Simonet WS, Lacey DL . Osteoclast differentiation and activation. Nature 2003; 423: 337–42.
Cronstein BN . Interleukin-6 — a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65: S11–5.
Acknowledgements
We thank Prof Dan-ping LIU (Liaoning Medical University, Jinzhou, China) for providing FLSs of RA patients. This study was supported by grants from the National Natural Science Foundation (No 81400875) and the Natural Science Foundation of Liaoning Province (No 2014022017).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jin, Xn., Yan, Ez., Wang, Hm. et al. Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. Acta Pharmacol Sin 37, 674–686 (2016). https://doi.org/10.1038/aps.2016.7
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.7
Keywords
This article is cited by
-
Polyene phosphatidylcholine ameliorates synovial inflammation: involvement of PTEN elevation and glycolysis suppression
Molecular Biology Reports (2023)
-
Inhibitory Effects of Cold Atmospheric Plasma on Inflammation and Tumor-Like Feature of Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis
Inflammation (2022)
-
Transient Receptor Potential Ankyrin 1 (TRPA1) Mediates Lipopolysaccharide (LPS)-Induced Inflammatory Responses in Primary Human Osteoarthritic Fibroblast-Like Synoviocytes
Inflammation (2018)
-
Hyperoside inhibits the effects induced by oxidized low-density lipoprotein in vascular smooth muscle cells via oxLDL-LOX-1-ERK pathway
Molecular and Cellular Biochemistry (2017)
-
Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis
Clinical and Experimental Medicine (2017)
